Cogstate test shows effective treatment choice for schizophrenia Medical technology company Cogstate continues to strengthen its position as an essential partner for measuring cognition in essential studies all over the world, with results from a schizophrenia study using Cogstate's check published in a significant scientific journal. In a peer examined paper released in the European Neuropsychopharmacology journal co-authored by Cogstate Chief Science Officer Dr Paul Maruff, it was reported that Lurasidone, an atypical antipsychotic medication, improved cognitive function of schizophrenia sufferers, as measured by the Cogstate exams, significantly more than the control group tadalis-sx.net .
‘Our brief, game-like testing are well approved by also the sickest children – for example, in an earlier study we found a lot more than 98 percent of kids with acute lymphoblastic leukemia could actually complete them. Previous methods using onerous paper and pencil tests yielded far lower adherence rates in sick children, resulting in missed opportunities to compare the dangers and benefits of various treatments. ‘Regulators had been encouraging the sponsor to add an onerous battery of paper and pencil tests in the trial; understandably, they were concerned about the ability of sick kids to comprehensive these. Cogstate was able to provide robust scientific support for the validity of the testing, and this was accepted by both sponsor and the regulator,’ Mr O'Connor said. Improved Clinical Trials Sales Activity The contract follows the award of US$1.2m in other contracts in the Clinical Trials business already signed since 1 January 2014, creating a total of US$2.6m worth of new contracts up to now in the 2014 calendar year.